Rifampicin Combination Therapy Versus Monotherapy for Staphylococcal Prosthetic Joint Infection

NCT06172010 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 316

Last updated 2023-12-15

No results posted yet for this study

Summary

In this Dutch multicenter clinical trial, patients with a staphylococcal prosthetic joint infection, will, in the oral antibiotic treatment phase, be randomized between clindamycin monotherapy and rifampicin / levofloxacin combination therapy. The clinical endpoint will be treatment success one year after finishing antimicrobial treatment.

Conditions

  • Prosthetic-joint Infection
  • Infection Hip
  • Infection; Knee, Joint

Interventions

DRUG

Clindamycin

antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection

DRUG

Rifampicin and levofloxacin

antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection

Sponsors & Collaborators

  • University Medical Center Groningen

    collaborator OTHER
  • Onze Lieve Vrouwe Gasthuis

    collaborator OTHER
  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER
  • Frisius Medisch Centrum

    collaborator OTHER
  • Isala

    collaborator OTHER
  • Martini Hospital Groningen

    collaborator OTHER
  • Radboud University Medical Center

    collaborator OTHER
  • Sint Maartenskliniek

    collaborator OTHER
  • Elisabeth-TweeSteden Ziekenhuis

    collaborator OTHER
  • Erasmus Medical Center

    collaborator OTHER
  • Alrijne Hospital

    collaborator OTHER
  • Spaarne Gasthuis

    collaborator OTHER
  • Reinier Haga Orthopedisch Centrum

    collaborator OTHER
  • Tergooi Hospital

    collaborator OTHER
  • Rijnstate Hospital

    collaborator OTHER
  • Leiden University Medical Center

    lead OTHER

Principal Investigators

  • Henk Scheper, MD · LUMC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2027-03-31
Completion
2028-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06172010 on ClinicalTrials.gov